Emergent BioSolutions has announced US$75 million investment plan to expand viral vector and gene therapy capabilities in its facility at Canton, Massachusetts.
This investment is part of the company’s bid to strengthen its Contract Development and Manufacturing (CDMO) capabilities by expanding viral and gene therapies.
The new facility mainly focuses on the manufacturing and expansion of live viral vaccines including smallpox vaccines. In addition, viral vector and gene therapy capabilities will increase campus footprint and build advanced therapy capability.
The facility includes state-of-the-art and multi-suite operation up to 1000L scale. With the addition of advanced therapy scale to the Canton facility, the company will build upon its biologics platforms complement its existing smallpox vaccine capabilities.